Patent ID: 6274550
Filing Date: 2001-08-14
Classification: G01N

Abstract:
A substantially pure azaftig wherein said azaftig is a proteoglycan of molecular weight about 24 kDa as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis; wherein said azaftig is obtained from or is identical to a proteoglycan obtained from urine of cachectic cancer patients; wherein said azaftig is a proteoglycan as determined by partial digestion with either chondroitinase ABC or chondroitinase AC; wherein said azaftig is not readily digested by neuraminidase; wherein said azaftig binds to fat cell membranes; wherein said azaftig does not bind to muscle cell membranes; and wherein said azaftig is a negatively charged molecule as determined by DEAE-Sephacel chromatography at pH 7.0.